James Trippi, MD
Cardiovascular Disease · Indianapolis, INNPI 1164488037
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $209,123 of the $239,352 with a category attached, or 87.4%. 16 manufacturers reported payments, led by Amgen at 44.8% of the total. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $1054.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$107K
- Regeneron Healthcare Solutions, Inc.$46K
- Amarin Pharma, Inc.$28K
- Esperion Therapeutics, Inc.$25K
- Ionis Pharmaceuticals, Inc.$15K
- Kaneka Medical America LLC$12K
- plus $5K from 10 others
Across 112 payments — averaging $1870.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$93K
- Ionis Pharmaceuticals, Inc.$46K
- Esperion Therapeutics, Inc.$23K
- AstraZeneca$20K
- Amryt Pharma Holdings Ltd$15K
- Chiesi USA, Inc.$8K
- plus $6K from 3 others
What the payments were for
- Consulting fees$16,3757%
- Speaking & faculty fees$209,12387%
- Travel & lodging$8,2103%
- Food & beverage$5,6442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 108 | $107,141 |
| Regeneron Healthcare Solutions, Inc. | 35 | $45,760 |
| Amarin Pharma, Inc. | 27 | $27,706 |
| Esperion Therapeutics, Inc. | 21 | $25,460 |
| Ionis Pharmaceuticals, Inc. | 14 | $15,407 |
| Kaneka Medical America LLC | 2 | $12,403 |
| Novartis | 5 | $3,242 |
| Akcea Therapeutics, Inc. | 1 | $1,820 |
| Heartflow, Inc. | 1 | $122 |
| Regeneron | 1 | $97 |
| Sanofi-aventis U.S. LLC | 4 | $70 |
| Pfizer | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$239,352 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 1,801 | $2,423,911 |
| Praluent PenAlirocumab | 432 | $532,734 |
| EliquisApixaban | 335 | $375,550 |
| VascepaIcosapent Ethyl | 166 | $110,351 |
| XareltoRivaroxaban | 70 | $90,079 |
| NexletolBempedoic Acid | 103 | $75,856 |
| EntrestoSacubitril/Valsartan | 56 | $51,667 |
| JardianceEmpagliflozin | 29 | $38,037 |
| NexlizetBempedoic Acid/Ezetimibe | 56 | $37,039 |
| Icosapent Ethyl | 106 | $24,308 |
| Ezetimibe | 1,054 | $22,566 |
| LivaloPitavastatin Calcium | 18 | $11,807 |
| FarxigaDapagliflozin Propanediol | 14 | $10,780 |
| Ranolazine ErRanolazine | 68 | $7,541 |
| Rosuvastatin Calcium | 644 | $6,828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $44 | $375,550335 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $25,460 | $112,895159 claims |
| Johnson & JohnsonXarelto | $18 | $90,07970 claims |
| NovartisEntresto | $3,242 | $51,66756 claims |
| AstraZenecaFarxiga | $15 | $10,78014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Vijay RaoIndianapolis$247K
- Atul ChughIndianapolis$242K
- Christopher HealyIndianapolis$209K
- Richard KovacsIndianapolis$136K
- George LolayIndianapolis$128K
- Onyedika IlonzeIndianapolis$125K
- Noel DasguptaIndianapolis$122K
- Anthony BashallIndianapolis$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.